The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Pathology Tissue Resource
Claire S. Zhu, Neal D. Freedman(National Institutes of Health), Asia Khan, Mark E. Sherman(Mayo Clinic in Florida), Shannon Pretzel(University of Colorado Cancer Center), Matthew Chaloux(Information Management Services), P Beckmann(IDEX Corporation (United States)), Sunitha Mathew(Westat (United States)), Danielle M. Carrick(National Institutes of Health), Deborah Multerer(Marshfield Clinic), Craig Williams(The University of Adelaide), Petra H. Lenz(University of Hawaiʻi at Mānoa), Paul F. Pinsky(National Cancer Institute), Kelly J. Yu(National Cancer Institute), Vanessa Olivo(Westat (United States)), Amanda Black(St. Elizabeth's Hospital), Amy Miller(University of Michigan), Christine D. Berg(National Cancer Institute), Wen‐Yi Huang(National Institutes of Health), Susan Yurgalevitch(United States Department of Health and Human Services), Karen Broski(Henry Ford Health System), Laura Hawkins(University of Birmingham), Robert N. Hoover(Tulane University)
Cited by 13
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective
|JNCI Journal of the National Cancer Institute|1995|3.4k
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
|Nature Genetics|2007|1.5k
Replicating genotype–phenotype associations
|Nature|2007|1.4k